These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 33186212)

  • 1. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
    Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP
    J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus Disease 2019 Vaccine Development: An Overview.
    Sumirtanurdin R; Barliana MI
    Viral Immunol; 2021 Apr; 34(3):134-144. PubMed ID: 32985963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
    Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
    Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
    Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
    Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in the development of SARS-CoV-2 vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines against COVID-19: Perspectives and challenges.
    Silveira MM; Moreira GMSG; Mendonça M
    Life Sci; 2021 Feb; 267():118919. PubMed ID: 33352173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.
    Kurup D; Schnell MJ
    Curr Opin Virol; 2021 Aug; 49():52-57. PubMed ID: 34049261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.